LONDON DAILY ARCHIVE

AstraZeneca Ends Late-Stage Lung Cancer Trial After Data Shows No Survival Benefit

AstraZeneca has stopped a Phase Three trial of an experimental bispecific antibody after interim results indicated the treatment would not improve survival, dealing a setback to the company’s plans for major revenue growth by the end of the decade.

18 August 2026 · 00:00 UTC